Showing 6 results for Opportunities
DARPA published its Young Faculty Award (YFA) 2018 Research Announcement today, seeking proposals in 26 different topic areas—the largest number of YFA research areas ever solicited.
DARPA has enjoyed a strong relationship with Silicon Valley since the early 1960s, working with innovators to lay the groundwork for new industries built around Agency investments in semiconductors, networking, artificial intelligence, user interfaces, programming, materials, microsystems, and more. Biotech is now emerging as a breakthrough opportunity space and it represents an area that is ripe for fresh collaboration among DARPA, the nation’s top researchers, venture capitalists, and entrepreneurs.
March 2, 2016,
Location upon request
DARPA has invested more than $200 million in support of President Obama's Brain Initiative since 2014. This Federal investment has accelerated the development of innovative neurotechnologies with the potential to improve human health and change the way people live, work, and play. On March 2, 2016, DARPA will host a small meeting of technology-minded investors, scientists, and entrepreneurs to showcase several current, cutting-edge neurotechnology efforts, consider future trajectories and potential applications, and encourage continued investment and eventual commercialization of some of these technologies. Space is limited. Interested parties with venture portfolios in this domain should email firstname.lastname@example.org
for more information and registration details.
This announcement seeks revolutionary research ideas for topics not being
addressed by ongoing BTO programs or other published solicitations.
Military service members and veterans face serious occupational trauma; one
element in particular relates to the significantly increased risk of acute
and chronic neuropsychiatric conditions. Neuropsychiatric conditions in the
military are particularly impactful because options for treating them are
limited. No therapy currently exists that can deliver rapid relief of
neuropsychiatric symptoms and is reasonable for use in a broad spectrum of
conditions. Neuropsychiatric conditions are complex, and presentation is
highly subject to significant inter-individual variability. Focused Pharma
aims to develop new drugs that target specific neurotransmitter receptor
signaling modes to deliver near immediate relief that is generalizable
across indications and individuals.